ClinicalTrials.gg
Not yet recruitingNCT07668674INDIGOUpdated Jun 25, 2026

Functional Brain MRI to Understand Pain Phenotypes in Knee Osteoarthritis

A Phase 2 interventional study of blood sampling and Resting-state functional MRI in Gonarthrosis and Neuropathic Pain, Nociceptive Pain, sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 3 sites in France. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by University Hospital, Clermont-Ferrand · Phase 2, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · University Hospital, Clermont-Ferrand.

Started
2026
the only one that year
Phase 2
Only one
of the 13
Registered
13th of 13
by date

Among the 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand, this one is the only one that started in 2026, is the only one in phase 2, and was the 13th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

Some people with knee osteoarthritis (gonarthrosis) experience pain differently. In some, the pain is described as "nociceptive" (directly related to the joint), while in others it has "neuropathic" characteristics (related to nerve function).

The goal of this multicenter, cross-sectional and comparative study is to compare resting brain activity in a brain region called the anterior insula among female patients with painful knee osteoarthritis who experience nociceptive pain compared to those with neuropathic pain.

Researchers will compare brain activity at rest between these two types of pain in women over 40 with painful knee osteoarthritis. A better understanding could help improve pain management in the future.

Participants will be asked to :

  • complete questionnaires during the inclusion visit and on the day of the scan,
  • undergo a clinical examination and a blood test at the inclusion visit,
  • undergo a functional MRI (fMRI), an imaging test that allows observation of brain activity at rest.

Paticipants in the study does not involve any additional treatment. the fMRI scan is non-invasive and does not require any injections.

Read the detailed description

This study will include patients with painful knee osteoarthritis (pain scoring ≥ 4/10 on the Numerical Rating Scale (NRS)). Patients matched by age (within 3 years) will be divided into two groups based on their PainDETECT score: those with nociceptive pain (score ≤ 12) and those with neuropathic pain (score > 13).

Participants will be recruited from three rheumatology centers (30 in Clermont-Ferrand, 15 at Saint-Antoine Hospital, and 15 at Pitié-Salpêtrière Hospital in Paris). The rheumatologist will verify eligibility and provide information during the pre-enrollment consultation, within 30 days prior to enrollment. After obtaining their informed consent, patients will attend the enrollment visit and be assigned to a group based on their PainDETECT score.

Each participant will undergo a clinical evaluation, including the following PRO measures: Lequesne and WOMAC functional indices, EuroQol EQ-5D, Hospital Anxiety and Depression Scale, fatigue and pain intensity scales, Catastrophizing Scale (PCS), ICOAP, OASIS, and Flare-OA scales. A QST test will also be performed using the Neogi method, which includes pressure pain thresholds, conditioned pain modulation, and temporal pain summation.

A blood test will be performed, including high-sensitivity CRP and metabolic markers (lipid profile, HbA1c, and fasting blood glucose), due to the link between metabolic syndrome and osteoarthritic pain.

Within 30 days of enrollment, participants will undergo an fMRI scan at the radiology department in Clermont-Ferrand or at La Pitié-Salpêtrière. On the day of the scan, participants will complete additional self-reports of knee pain using the questionnaires. Interpretation of the fMRI data will be centralized in Clermont-Ferrand.

03

Conditions studied

  • Gonarthrosis
  • Neuropathic Pain, Nociceptive Pain

Keywords

  • Gonarthrosis
  • Neuropathic pain
  • Nociceptive Pain
  • Functional MRI
  • Anterior insula
  • Brain activity in the anterior insula at rest
  • INDIGO
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 40 or older (only women will be included to ensure consistency in the analyses, given the higher prevalence of osteoarthritis in women and the influence of sex/gender on the experience of pain)
  • Diagnosis of femorotibial osteoarthritis of the knee according to the 1986 American College of Rheumatology criteria
  • Presence of knee pain with an intensity of ≥ 4/10 on a numerical rating scale (NRS)
  • Chronic knee pain, i.e., lasting at least 6 months with at least 15 days of pain in the past 30 days
  • Completion of the PainDETECT questionnaire, which will allow the patient to be assigned to one of two groups prior to the enrollment visit (those with nociceptive pain [score ≤ 12] and those with neuropathic pain [score > 13])
  • Patients have read and understood the information letter
  • Patients have signed the form
  • Patients are enrolled in a social security program

Exclusion criteria

Exclusion Criteria:

  • Other joint diseases affecting the knees (gout, chondrocalcinosis, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis)
  • Conditions that, in the investigator's opinion, interfere with the assessment of osteoarthritic pain, such as conditions causing neuropathic pain in the lower extremities (e.g., peripheral neuropathy, chronic radiculopathy) or fibromyalgia
  • Kellgren-Lawrence radiographic stage IV in one or both knees
  • Patients with one or more knee prostheses
  • Claustrophobia making MRI impossible
  • to MRI
  • Pregnant or breastfeeding women
  • Patients under guardianship, conservatorship, deprived of liberty, or under judicial protection
  • Patients who have participated in an interventional clinical trial within the last 6 months that could impact the primary endpoint
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Nociceptive pain knee osteroarthritis

    Participants with painful knee osteoarthritis classified as having nociceptive pain based on PainDETECT questionnaire score ≤12.

    Biological: blood sampling · Procedure: Resting-state functional MRI

  • Other
    Neuropathic-like pain knee osteoarthritis

    Participants with painful knee osteoarthritis classified as having neuropathic-like pain based on PainDETECT questionnaire score \>13.

    Biological: blood sampling · Procedure: Resting-state functional MRI

Interventions

  • Biologicalblood sampling

    Blood sampling will be performed at the inclusion visit. A biological assessment will include high sensitivity C reactive protein (hs-CRP) and metabolic markers (lipid profile, HbA1c, and fasting glucose). Additional blood samples (4 tubes) will be collected for biobank, including plasma and serum storage for the measurement of inflammatory markers.

  • ProcedureResting-state functional MRI

    Resting-state functional brain MRI will be performed at Visit 2 (within 30 days of the screening visit). Participants will undergo a brain MRI acquisition at rest to evaluate anterior insula activity and functional connectivity with pain-related brain regions.

06

What researchers measure

Primary outcomes

  1. Resting-state anterior insula activity measured by functional MRI (BOLD signal amplitude)

    Comparison of resting-state anterior insula brain activity between patients with painful knee osteoarthritis with nociceptive pain and those with neuropathic-like pain, classified using the painDETECT questionnaire.

    Time frame: At Visit 2 : within 30 days after inclusion, following Visit 1

Secondary outcomes

  1. Functional connectivity of the anterior insula with pain-related brain regions (resting-state MRI)

    Functional connectivity between the anterior insula (seed region) and predefined pain-related brain regions (S1, M1, posterior incula, ACC, MCC, vmPFC, DLPFC, thalamus) will be quantified using seed-basing resting-state fMRI analysis. Connectivity values will be expressed as Fisher-transformed correlation coefficients (z-scores).

    Time frame: At Visit 2 : within 30 days after inclusion

  2. Correlation between clinical pain scores ans anterior insula activity (resting-state fMRI)

    Correlation between clinical pain measures collected at visit 1 (painDETECT score, BAS pain intensity, WOMAC pain subscale, ICOAP score) and anterior insula activity measured at visit 2. Anterior insula activity will be quantified using the beta coefficient from the general linear model (GLM) of resting-state fMRI.

    Time frame: Clinical measures at Visit 1 and imaging measures at Visit 2 (within 30 days after inclusion)

  3. Correlation between clinical pain scores ans anterior insula functional connectivity (resting-state fMRI)

    Correlation between clinical pain measures collected at visit 1 (painDETECT, VAS, WOMAC, ICOAP) and functional connectivity z-scores between the anterior insula ans pain-related brain regions measured at visit 2.

    Time frame: Clinical measures at visit 1 ; imaging at visit 2 (within 30 days after inclusion)

Other outcomes

  1. Patient clusters identified using multimodal analysis including functional MRI and clinical data

    Identification of patient subgroups based on multimodal integration of imaging and clinical variables

    Time frame: Data collected at Visit 1 and Visit 2 (within 30 days after inclusion)

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Aug 2028, 25 months later.

Of 43 non-industry phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's planned 25 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
Jun 25, 2026
StartEst.
Jul 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07668674
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jul 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Jun 25, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
0473754963
Sylvain MATHIEU
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion